We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,177.25 +9.75 (+0.19%) Dow Futures
38,298.00 +60.00 (+0.16%) Nasdaq Futures
18,215.50 +36.25 (+0.20%) Russell 2000 Futures
2,028.80 +9.00 (+0.45%) Crude Oil
85.37 -0.29 (-0.34%) Gold
2,370.00 -4.10 (-0.17%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 270.00 |
| Open | 268.77 |
| Bid | 267.23 x 100 |
| Ask | 267.35 x 200 |
| Day's Range | 266.17 - 269.30 |
| 52 Week Range | 211.71 - 329.72 |
| Volume | |
| Avg. Volume | 2,944,187 |
| Market Cap | 143.24B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | 21.42 |
| EPS (TTM) | 12.48 |
| Earnings Date | May 02, 2024 |
| Forward Dividend & Yield | 9.00 (3.37%) |
| Ex-Dividend Date | May 16, 2024 |
| 1y Target Est | 308.33 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AMGN
Related Research
- Amgen Inc.Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.RatingFair ValueEconomic Moat28 days agoArgus Research
ZacksAmgen (AMGN) Laps the Stock Market: Here's Why
In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.
Motley FoolIs Amgen Stock a Buy?
Amgen's stock isn't expensive, but the business does face some challenges, which could have investors thinking twice.
MarketWatchThis weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema
Insider Monkey11 Best Biotech ETFs To Buy
In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]
InvestorPlaceThe 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
Looking ahead, the future of the U.S. economy appears promising despite ongoing challenges. President Biden’s efforts to steer the economy through inflation concerns are showing strong results. Recent data indicates a healthy economic position, with significant GDP growth outpacing other developed nations. Despite fluctuations in inflation and interest rates, the U.S. labor market remains resilient, adding jobs at a rapid pace. The country’s economic resilience, bolstered by substantial fiscal s
TheStreetFund manager of $100 million long/short mutual fund explains pair trade strategy
Joseph Artuso of Easterly Investment Partners knows how to hedge a portfolio.
Insider Monkey10 Best Weight Loss Drug Stocks to Buy Now
In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]
Insider Monkey13 Best Cheap Dividend Stocks To Buy Right Now
In this article, we discuss 13 best cheap dividend stocks to buy right now. You can skip our detailed analysis of value dividend stocks and overall performance of dividend stocks, and go directly to read 5 Best Cheap Dividend Stocks To Buy Right Now. Growth stocks took the lead in 2023, driven by the ‘Magnificent […]
Motley Fool2 Biotech Stocks to Buy Hand Over Fist in April
These drugmakers have made important moves over the past year.
ZacksAmgen (AMGN) Ascends But Remains Behind Market: Some Facts to Note
Amgen (AMGN) concluded the recent trading session at $269.95, signifying a +0.69% move from its prior day's close.
Morningstar Rating
Rating
Fair Value
Economic Moat
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| BIIB Biogen Inc. | |||
| GILD Gilead Sciences, Inc. | |||
| BMY Bristol-Myers Squibb Company | |||
| MRK Merck & Co., Inc. | |||
| LLY Eli Lilly and Company |
Similar to AMGN
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| ABBV AbbVie Inc. | |||
| MRK Merck & Co., Inc. | |||
| GILD Gilead Sciences, Inc. | |||
| BMY Bristol-Myers Squibb Company | |||
| BIIB Biogen Inc. |
Analyst Price Targets (23)
Upgrades & Downgrades
| Reiterates | Truist Securities: Buy to Buy | 4/12/2024 | |
| Reiterates | RBC Capital: Outperform to Outperform | 4/3/2024 | |
| Maintains | Goldman Sachs: Buy to Buy | 2/8/2024 | |
| Maintains | RBC Capital: Outperform to Outperform | 2/7/2024 | |
| Maintains | Goldman Sachs: Buy to Buy | 2/7/2024 | |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 2/7/2024 |
Company Profile
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com
Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full Time Employees: 26,700
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
